Thiotepa-melphalan myeloablative therapy for high-risk neuroblastoma.

Fumito Yamazaki Kai YamasakiChikako KiyotaniYoshiko HashiiYoko ShiodaJunichi HaraKimikazu Matsumoto

Published in: Pediatric blood & cancer (2021)

The thiotepa-melphalan high-dose therapy with thiotepa and melphalan may be effective for high-risk neuroblastoma. However, this regimen is toxic and warrants special attention in clinical practice.

Keyphrases

high dose
stem cell transplantation
low dose
clinical practice
working memory
allogeneic hematopoietic stem cell transplantation
bone marrow